Doubters feel the fury of a triumphant Furiex Pharmaceuticals, as shares popped by 66% in a single day. In the following video, Motley Fool health-care analyst David Williamson explains how approval of a trio of diabetes drugs for Takeda was responsible for this pop and takes a closer look at Furiex as an investment.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why shares popped 66% on Monday.
David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Merck
MRK
$79.26
(-0.04%)
$0.03
Bristol Myers Squibb
BMY
$46.86
(0.04%)
$0.02
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.